BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35263042)

  • 1. Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.
    Borowitz MJ; Wood BL; Keeney M; Hedley BD
    Curr Protoc; 2022 Mar; 2(3):e383. PubMed ID: 35263042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.
    Keeney M; Wood BL; Hedley BD; DiGiuseppe JA; Stetler-Stevenson M; Paietta E; Lozanski G; Seegmiller AC; Greig BW; Shaver AC; Mukundan L; Higley HR; Sigman CC; Kelloff G; Jessup JM; Borowitz MJ
    Cytometry B Clin Cytom; 2018 Mar; 94(2):239-249. PubMed ID: 28475275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
    Cherian S; Soma LA
    Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
    Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
    Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
    Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
    Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
    Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
    Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
    Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
    Irving J; Jesson J; Virgo P; Case M; Minto L; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N; Lawson S; ;
    Haematologica; 2009 Jun; 94(6):870-4. PubMed ID: 19377076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
    Luria D; Rosenthal E; Steinberg D; Kodman Y; Safanaiev M; Amariglio N; Avigad S; Stark B; Izraeli S;
    Cytometry B Clin Cytom; 2010 Nov; 78(6):365-71. PubMed ID: 20632326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Chatterjee G; Patkar N
    Br J Haematol; 2023 Feb; 200(3):277-279. PubMed ID: 36282207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
    Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
    Vinhas E; Lucena-Silva N; Pedrosa F
    Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2023 Mar; 43(1):115-125. PubMed ID: 36764804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
    Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
    Liu Z; Li Y; Shi C
    Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.